Patient‐reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial is a research paper published in Cancer Medicine (2020). On theSindex it has a DataRank of 0.523. It has been cited 9 times, with 9 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.345
From this paper's citation signal
Citation Network Contribution
0.177
From 9 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 9 citers.
National Cancer Institute
Grant: CA122061
National Cancer Institute
Grant: CA180790
National Cancer Institute
Grant: CA180794
National Cancer Institute
Grant: CA180799
National Cancer Institute
Grant: CA180802
National Cancer Institute
Grant: CA180820
National Cancer Institute
Grant: CA180864
National Cancer Institute
Grant: CA189828
National Cancer Institute
Grant: CA189830
National Cancer Institute
Grant: CA189863
National Cancer Institute
Grant: CA189971
NCI NIH HHS
Grant: U10 CA180820
NCI NIH HHS
Grant: UG1 CA189828
NCI NIH HHS
Grant: U10 CA180790
NCI NIH HHS
Grant: U10 CA180864
NCI NIH HHS
Grant: UG1 CA189830
NCI NIH HHS
Grant: U10 CA180794
NCI NIH HHS
Grant: T32 CA122061
NCI NIH HHS
Grant: U10 CA180799
NCI NIH HHS
Grant: U10 CA180802
NCI NIH HHS
Grant: R25 CA122061
NCI NIH HHS
Grant: UG1 CA189863
NCI NIH HHS
Grant: UG1 CA189971
NCI NIH HHS
Grant: UG1 CA233277
Fields of Study
MeSH Terms
Keywords